Episode 91 with Dr. Jorge Nogales-Gaete on MS patients' perceptions and needs
Unpredictability, vulnerability, fear, but also hope -- all are aspects of living with and treating MS.
People
Episode 90 with Dr. Daniel Hartung on pricing trends for MS disease-modifying therapies in the US
In most consumer markets, the price of products tends to go down over time, but pharmaceuticals don't always behave that way. Dr. Daniel Hartung shares what he learned from examining wholesale prices of MS drugs.
Drug Development
Episode 89 with Dr. Charity Evans on the effect of beta-interferon on hospital event rates
In addition to reducing MS disease activity, beta interferon drugs may also help people with MS avoid being hospitalized for respiratory infections.
Clinical Research
Making an injection tracking mobile app, need feedback!
I’ve been browsing various MS forums since my girlfriend started taking Copaxone for her MS last year, and see a lot of people asking about mobile apps or different methods of tracking their injections.
Episode 83 with Dr. Jerry Wolinsky on composite clinical trial outcome measures
MS researchers have been looking to composite endpoints as more sensitive and meaningful measures of MS progression and disability for testing new drugs.
Clinical Research, Drug Development
Papers: 16 May 2016 - 23 May 2016
Editors' Pick
Episode 82 with Dr. Adam Kaplin on depression & MS
Depression may be the leading cause of disability and death among people with MS. Importantly, it's one of the few MS symptoms that can—and should— be completely reversed through treatment, says Adam Kaplin MD PhD.
Clinical Research
European Multiple Sclerosis Platform 2016 Spring Conference
17 May 2016 to 18 May 2016
Oslo, Norway
Episode 81 with Dr. Kaarina Kowalec
Still in early days in MS, pharmacogenomics may have the potential optimize the risk/benefit profile in a patient's favor, focusing first on the risk of liver injury with interferon-beta.
Clinical Research, Drug Development
Pages
